CareDx (CDNA) stock price is $67.08, up 4.81% on the day, as of Oct 19, 2026. It has a market cap of $3.45Bn and a P/E ratio of 31.08, and is classified in the Diagnostic Labs industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.45 Bn
P/E31.08
P/S7.53
Div. Yield0.00
Revenue Growth (1y) (Qtr)52.23
Add ratio to table…
About
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The company delivers solutions that empower clinicians and improve patient outcomes. Its integrated portfolio includes noninvasive molecular testing for heart kidney and lung transplants laboratory products digital health technologies and patient support services before and after transplant. Headquartered in Brisbane California with additional operations…
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The company delivers solutions that empower clinicians and improve patient outcomes. Its integrated portfolio includes noninvasive molecular testing for heart kidney and lung transplants laboratory products digital health technologies and patient support services before and after transplant. Headquartered in Brisbane California with additional operations in Omaha Nebraska and Stockholm Sweden CareDx operates as a single reportable segment. The firm was incorporated in December 1998 and has undergone several name changes before becoming CareDx in March 2014. As of the end of 2025 the company employed approximately seven hundred sixty five people across research development manufacturing sales and administrative functions. CareDx’s mission centers on delivering actionable biological information that helps clinicians make informed decisions about immunosuppression therapy and graft surveillance.
CareDx generates revenue primarily from its testing services laboratory products and patient and digital solutions. Testing services include AlloSure Kidney AlloMap Heart AlloSure Heart HeartCare and AlloSure Lung which are reimbursed by Medicare private payers and Medicaid. The AlloSure Kidney test measures donor derived cell free DNA to detect early signs of kidney allograft injury and rejection. AlloMap Heart uses gene expression profiling to assess the probability of moderate to severe acute cellular rejection in heart transplant recipients. HeartCare combines AlloMap Heart and AlloSure Heart to provide a combined assessment of immune activation and graft injury. Laboratory products consist of HLA typing kits such as QTYPE Olerup SSP SBT and next generation sequencing based offerings like AlloSeq Tx AlloSeq HCT and AlloSeq cfDNA sold to hospitals and reference laboratories. QTYPE provides rapid human leukocyte antigen typing using polymerase chain reaction technology for deceased donor workflows. Olerup SSP SBT kits support low to high resolution HLA sequencing for transplant matching. AlloSeq Tx delivers high resolution HLA typing via hybrid capture sequencing covering additional non HLA genes relevant to transplant outcomes. AlloSeq HCT measures chimerism in stem cell transplant recipients to monitor engraftment and detect potential relapse. AlloSeq cfDNA quantifies donor derived cell free DNA in blood for surveillance across multiple organ types. Patient and digital solutions comprise workflow software such as Ottr Organ and Ottr Cellular referral management tools like TxAccess quality reporting platforms like XynQAPI medication adherence programs like MedActionPlan and the CareDx pharmacy service. Ottr Organ and Ottr Cellular integrate with electronic medical records to streamline transplant waitlist management and post transplant care coordination. TxAccess enables nephrologists and dialysis centers to submit electronic referrals to transplant programs and track patient progress through the waitlist. XynQAPI simplifies quality metric tracking and reporting to the Scientific Registry of Transplant Recipients. MedActionPlan offers personalized medication management tools to improve adherence and reduce graft loss risk. The CareDx pharmacy provides specialized medication dispensing counseling and insurance navigation for transplant patients. Revenue is derived from test fees product sales and subscription or service fees for digital platforms.
CareDx holds a leading position in the transplant diagnostics market as the premier provider of genomics based information for transplant recipients. The company differentiates itself through an integrated go to market model that targets a concentrated network of transplant centers and offers a broad portfolio of solutions that can be cross sold within the same institution. This approach reduces customer acquisition costs and increases utilization of its tests. Competitors in the molecular diagnostics space include Natera Eurofins Transplant Genomics Devyser and Insight Molecular Diagnostics. In the HLA typing arena the firm faces competition from Thermo Fisher through its One Lambda business as well as from Omixon GenDx BAG Qiagen and Immucor. For digital health solutions rivals include Phoenix the Epic transplant application TREX and MedSleuth. CareDx’s competitive advantages stem from its strong clinical validation data robust reimbursement relationships with Medicare and private payers its proprietary technology platform and its deep expertise in transplant immunology and workflow optimization. The firm has secured favorable coverage decisions for its major tests from Medicare Administrative Contractors and numerous private payer policies. Its ability to bundle multiple assays into a single patient encounter enhances convenience for clinicians and encourages broader adoption. Continuous investment in research and development supports a pipeline of next generation assays that address unmet needs in transplant surveillance and adjacent therapeutic areas. These factors together create a barrier to entry for new entrants seeking to replicate CareDx’s integrated service model.
CareDx serves transplant centers hospitals laboratories and patients across the United States and Europe. Its software platforms are used in more than 170 transplant centers in the U. S. The company’s testing products are ordered by clinicians managing heart kidney and lung transplant recipients while its laboratory kits are utilized by histocompatibility and immunogenetics laboratories for donor recipient matching and post transplant surveillance. Patient facing services such as the pharmacy and medication adherence programs support individuals undergoing transplantation and their caregivers. Although specific customer names are not disclosed in the filing the base includes academic medical centers community hospitals and specialty transplant programs. Geographically the majority of revenue is generated in the United States with a growing presence in European markets particularly Sweden and other Nordic countries. The company’s laboratory in Brisbane California processes approximately two hundred thousand tests annually supporting a large volume of transplant surveillance. Its manufacturing site in Stockholm Sweden produces HLA typing kits and next generation sequencing based products for distribution to global customers. By focusing on a defined customer group of transplant providers CareDx builds long term relationships that facilitate repeat business and upsell opportunities.
Sectors:Healthcare·TechnologySector rationaleCareDx's primary revenue is derived from medical diagnostic testing services (e.g., AlloSure, AlloMap) and laboratory products (HLA typing kits) sold to hospitals and laboratories for transplant patient care. A secondary sector of Technology is justified because the company sells a substantial line of standalone digital health and workflow software platforms, such as Ottr Organ and XynQAPI, which are sold via subscription or service fees.Industries:Diagnostic LabsDiagnostic LabsPrimaryCareDx generates significant revenue from providing clinical diagnostic testing services, such as AlloSure Kidney and AlloMap Heart, which are performed in its Brisbane, California laboratory and reimbursed by Medicare and private payers.Diagnostic EquipmentDiagnostic EquipmentSecondaryThe company manufactures and sells diagnostic laboratory products and kits, including HLA typing kits like QTYPE and next-generation sequencing offerings like AlloSeq Tx, to hospitals and reference laboratories.Healthcare ITHealthcare ITSecondaryCareDx sells healthcare-specific software platforms such as Ottr Organ, Ottr Cellular, and XynQAPI, which are designed for transplant waitlist management, care coordination, and quality reporting within transplant centers.Classified using BQ-MICSCIK: 0001217234
Bull & bear
Investment Thesis
▲ Bull case
The Navaris acquisition is a transformative move that extends CareDx’s precision diagnostics model into viral-mediated oncology, a $4.5B TAM with minimal competition and existing Medicare reimbursement at $1,800 per test. While the market may view this as a bolt-on acquisition, the strategic fit is far deeper: Navaris operates in a niche where longitudinal monitoring is already embedded in clinical workflows, mirroring CareDx’s transplant model. The company’s ability to leverage its existing infrastructure—such as Epic integrations, repeat testing protocols, and specialty provider relationships—could accelerate Navaris’ 30-40% growth trajectory beyond expectations. The acquisition also diversifies CareDx’s revenue streams, reducing reliance on transplant volumes, which have been sluggish. Importantly, Navaris’ technology is tumor-naïve, eliminating the need for tissue samples and simplifying adoption, a key differentiator in liquid biopsy markets where competitors often require complex workflows. The market may underestimate how quickly CareDx can scale Navaris by embedding it into the same subspecialty channels it has mastered in transplant, particularly ENTs and medical oncologists managing HPV-driven cancers.
CareDx’s transplant business is benefiting from structural shifts in testing adoption that are independent of transplant procedure volumes. The company’s testing volumes grew 17% in Q1 FY26 despite flat underlying transplant procedures, underscoring the durability of its model. This growth is driven by increasing penetration of for-cause testing in kidney transplants, which now accounts for 50% of kidney testing volume, and the expansion of HeartCare and lung transplant monitoring. The market may be underestimating the stickiness of CareDx’s testing services, as once a patient enters the transplant ecosystem, they require lifelong monitoring. Even modest increases in testing adherence—driven by workflow integrations like Epic Aura—can compound into significant revenue growth over time. Additionally, the company’s digital solutions and patient engagement tools, which are used by 70% of transplant centers, create a moat by deepening integration into clinical workflows. The more solutions a center adopts, the higher the testing volumes, creating a virtuous cycle. The market may also be overlooking the potential for AlloSure liver to expand into a new organ system, further broadening CareDx’s TAM in transplant.
The divestiture of the Lab Products business and the $170M upfront cash from the Navaris deal provide financial flexibility that could unlock shareholder value. The Lab Products divestiture simplifies CareDx’s operating model, allowing it to focus on its higher-margin testing services and digital solutions, which grew 48% and 33% YoY in Q1 FY26, respectively. The $160M net proceeds from the divestiture, combined with the $198M cash balance at quarter-end, give the company ample dry powder for tuck-in acquisitions or share repurchases. The $100M share repurchase program authorized by the board signals confidence in the company’s cash flow generation and could provide a floor for the stock. The market may be underappreciating how these portfolio actions could drive margin expansion, particularly as the company scales its higher-margin testing services and reduces operating complexity.
CareDx’s evidence generation strategy is creating a flywheel effect that could sustain long-term growth. The company’s focus on interventional studies like MERIT, which evaluates how molecular insights inform therapeutic decisions, is critical for embedding its tests into clinical guidelines. The recent presentation of over 50 abstracts at ISHLT, including data from large registries like SHORE and ALAMO, demonstrates the growing body of evidence supporting molecular monitoring in transplant. This scientific momentum is often overlooked by investors who focus on near-term revenue growth, but it is a key driver of long-term adoption. Similarly, Navaris’ platform is backed by 56 peer-reviewed publications, including a large real-world study showing a 98% negative predictive value and a 4-month lead time in detecting recurrence. This level of clinical validation is rare in liquid biopsy markets and could accelerate adoption as providers become more comfortable with the technology. The market may be underestimating how CareDx’s disciplined approach to evidence generation can drive sustained growth across both transplant and oncology.
The company’s improving revenue cycle management and cash collections are a hidden catalyst for margin expansion. In Q1 FY26, CareDx collected $14M in excess of December 31 receivables, contributing $260 per test to revenue. While this out-of-period revenue is expected to normalize, the underlying trend of improving cash collections—up 52% YoY—reflects operational efficiencies that could drive sustainable margin expansion. The company’s guidance assumes revenue per test will increase to $14.60 by year-end, driven by higher accrual rates and improved collections. The market may be underestimating how these operational improvements, combined with the divestiture of lower-margin Lab Products, could drive adjusted EBITDA margins higher than the current 10-12% range.
The Navaris acquisition is a transformative move that extends CareDx’s precision diagnostics model into viral-mediated oncology, a $4.5B TAM with minimal competition and existing Medicare reimbursement at $1,800 per test. While the market may view this as a bolt-on acquisition, the strategic fit is far deeper: Navaris operates in a niche where longitudinal monitoring is already embedded in clinical workflows, mirroring CareDx’s transplant model. The company’s ability to leverage its existing infrastructure—such as Epic integrations, repeat testing protocols, and specialty provider relationships—could accelerate Navaris’ 30-40% growth trajectory beyond expectations. The acquisition also diversifies CareDx’s revenue streams, reducing reliance on transplant volumes, which have been sluggish. Importantly, Navaris’ technology is tumor-naïve, eliminating the need for tissue samples and simplifying adoption, a key differentiator in liquid biopsy markets where competitors often require complex workflows. The market may underestimate how quickly CareDx can scale Navaris by embedding it into the same subspecialty channels it has mastered in transplant, particularly ENTs and medical oncologists managing HPV-driven cancers.
CareDx’s transplant business is benefiting from structural shifts in testing adoption that are independent of transplant procedure volumes. The company’s testing volumes grew 17% in Q1 FY26 despite flat underlying transplant procedures, underscoring the durability of its model. This growth is driven by increasing penetration of for-cause testing in kidney transplants, which now accounts for 50% of kidney testing volume, and the expansion of HeartCare and lung transplant monitoring. The market may be underestimating the stickiness of CareDx’s testing services, as once a patient enters the transplant ecosystem, they require lifelong monitoring. Even modest increases in testing adherence—driven by workflow integrations like Epic Aura—can compound into significant revenue growth over time. Additionally, the company’s digital solutions and patient engagement tools, which are used by 70% of transplant centers, create a moat by deepening integration into clinical workflows. The more solutions a center adopts, the higher the testing volumes, creating a virtuous cycle. The market may also be overlooking the potential for AlloSure liver to expand into a new organ system, further broadening CareDx’s TAM in transplant.
The divestiture of the Lab Products business and the $170M upfront cash from the Navaris deal provide financial flexibility that could unlock shareholder value. The Lab Products divestiture simplifies CareDx’s operating model, allowing it to focus on its higher-margin testing services and digital solutions, which grew 48% and 33% YoY in Q1 FY26, respectively. The $160M net proceeds from the divestiture, combined with the $198M cash balance at quarter-end, give the company ample dry powder for tuck-in acquisitions or share repurchases. The $100M share repurchase program authorized by the board signals confidence in the company’s cash flow generation and could provide a floor for the stock. The market may be underappreciating how these portfolio actions could drive margin expansion, particularly as the company scales its higher-margin testing services and reduces operating complexity.
CareDx’s evidence generation strategy is creating a flywheel effect that could sustain long-term growth. The company’s focus on interventional studies like MERIT, which evaluates how molecular insights inform therapeutic decisions, is critical for embedding its tests into clinical guidelines. The recent presentation of over 50 abstracts at ISHLT, including data from large registries like SHORE and ALAMO, demonstrates the growing body of evidence supporting molecular monitoring in transplant. This scientific momentum is often overlooked by investors who focus on near-term revenue growth, but it is a key driver of long-term adoption. Similarly, Navaris’ platform is backed by 56 peer-reviewed publications, including a large real-world study showing a 98% negative predictive value and a 4-month lead time in detecting recurrence. This level of clinical validation is rare in liquid biopsy markets and could accelerate adoption as providers become more comfortable with the technology. The market may be underestimating how CareDx’s disciplined approach to evidence generation can drive sustained growth across both transplant and oncology.
The company’s improving revenue cycle management and cash collections are a hidden catalyst for margin expansion. In Q1 FY26, CareDx collected $14M in excess of December 31 receivables, contributing $260 per test to revenue. While this out-of-period revenue is expected to normalize, the underlying trend of improving cash collections—up 52% YoY—reflects operational efficiencies that could drive sustainable margin expansion. The company’s guidance assumes revenue per test will increase to $14.60 by year-end, driven by higher accrual rates and improved collections. The market may be underestimating how these operational improvements, combined with the divestiture of lower-margin Lab Products, could drive adjusted EBITDA margins higher than the current 10-12% range.
The Navaris acquisition introduces significant execution risks and could dilute CareDx’s focus on its core transplant business. While Navaris operates in a niche with existing reimbursement, its growth is highly dependent on expanding adoption in HPV-driven cancers, where providers may still prefer traditional diagnostic methods like imaging or tissue biopsies. The market may be overestimating CareDx’s ability to scale Navaris’ platform, particularly given the company’s limited experience in oncology. Additionally, Navaris’ $34M in 2025 revenue is a fraction of CareDx’s $447-465M guidance for FY26, and integrating a business with a fundamentally different clinical workflow could strain resources. The acquisition also comes with operational risks, including the need to automate Navaris’ lab workflows to reduce cost per test, which could require significant capital expenditure. If CareDx fails to execute on these integration challenges, Navaris could become a drag on margins rather than a growth driver.
CareDx’s transplant business is vulnerable to reimbursement cuts and competitive threats that could erode its pricing power. The company is awaiting a final LCD from MolDX, which could impose pricing cuts on its transplant tests as early as Q3 FY26. While management has guided for a $7.5M revenue impact from the LCD, the actual cut could be deeper, particularly if Medicare seeks to align reimbursement with lower-cost alternatives. Competitors like Natera and Eurofins are also expanding their transplant monitoring offerings, which could pressure CareDx’s market share, especially in kidney transplant, where for-cause testing is becoming commoditized. The market may be ignoring the risk that transplant centers could switch to lower-cost providers if CareDx’s tests are not deemed clinically superior. Additionally, the company’s reliance on repeat testing volumes assumes transplant centers will continue to adhere to surveillance protocols, but budget constraints or changes in clinical guidelines could reduce testing frequency, impacting revenue.
The company’s growth in transplant testing is increasingly tied to factors outside its control, including transplant procedure volumes and regulatory incentives. While CareDx has grown testing volumes despite flat transplant procedures, this trend may not be sustainable if procedure volumes decline. The company has cited chatter about increased transplant volumes due to the IOTA program, but there is no guarantee these incentives will translate into higher procedures nationwide. If transplant volumes stagnate or decline, CareDx’s testing growth could slow, particularly as it exhausts the pool of existing transplant patients who are not yet using its tests. The market may also be overlooking the risk that transplant centers could reduce testing frequency if they perceive the clinical utility of CareDx’s tests to be marginal, particularly in lung transplant, where adoption remains low.
The Navaris acquisition introduces significant execution risks and could dilute CareDx’s focus on its core transplant business. While Navaris operates in a niche with existing reimbursement, its growth is highly dependent on expanding adoption in HPV-driven cancers, where providers may still prefer traditional diagnostic methods like imaging or tissue biopsies. The market may be overestimating CareDx’s ability to scale Navaris’ platform, particularly given the company’s limited experience in oncology. Additionally, Navaris’ $34M in 2025 revenue is a fraction of CareDx’s $447-465M guidance for FY26, and integrating a business with a fundamentally different clinical workflow could strain resources. The acquisition also comes with operational risks, including the need to automate Navaris’ lab workflows to reduce cost per test, which could require significant capital expenditure. If CareDx fails to execute on these integration challenges, Navaris could become a drag on margins rather than a growth driver.
CareDx’s transplant business is vulnerable to reimbursement cuts and competitive threats that could erode its pricing power. The company is awaiting a final LCD from MolDX, which could impose pricing cuts on its transplant tests as early as Q3 FY26. While management has guided for a $7.5M revenue impact from the LCD, the actual cut could be deeper, particularly if Medicare seeks to align reimbursement with lower-cost alternatives. Competitors like Natera and Eurofins are also expanding their transplant monitoring offerings, which could pressure CareDx’s market share, especially in kidney transplant, where for-cause testing is becoming commoditized. The market may be ignoring the risk that transplant centers could switch to lower-cost providers if CareDx’s tests are not deemed clinically superior. Additionally, the company’s reliance on repeat testing volumes assumes transplant centers will continue to adhere to surveillance protocols, but budget constraints or changes in clinical guidelines could reduce testing frequency, impacting revenue.
The company’s growth in transplant testing is increasingly tied to factors outside its control, including transplant procedure volumes and regulatory incentives. While CareDx has grown testing volumes despite flat transplant procedures, this trend may not be sustainable if procedure volumes decline. The company has cited chatter about increased transplant volumes due to the IOTA program, but there is no guarantee these incentives will translate into higher procedures nationwide. If transplant volumes stagnate or decline, CareDx’s testing growth could slow, particularly as it exhausts the pool of existing transplant patients who are not yet using its tests. The market may also be overlooking the risk that transplant centers could reduce testing frequency if they perceive the clinical utility of CareDx’s tests to be marginal, particularly in lung transplant, where adoption remains low.